{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,23]],"date-time":"2023-10-23T09:11:32Z","timestamp":1698052292150},"reference-count":25,"publisher":"Wiley","issue":"S2","license":[{"start":{"date-parts":[[2012,7,26]],"date-time":"2012-07-26T00:00:00Z","timestamp":1343260800000},"content-version":"vor","delay-in-days":8517,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[1989,4]]},"abstract":"<jats:p>1. The effects of heart failure due to chronic myocardial infarction on the responsiveness to injected angiotensin I and ACE inhibition by intravenous cilazapril (1 mg kg\u20101) were evaluated. 2. For this purpose one group of 17 rats with a 4\u2010week old myocardial infarction was compared with a group of 10 sham operated rats. 3. Heart failure increased markedly the responsiveness of the renal and mesenteric vascular beds to ACE inhibition which produced a vasodilation in these two vascular beds. 4. This increased responsiveness was most likely due to a stimulation of the renin\u2010angiotensin system without any change of sensitivity to angiotensin I of the renal and mesenteric vascular beds. 5. Cilazapril produced the same level of ACE inhibition in both groups of rats.<\/jats:p>","DOI":"10.1111\/j.1365-2125.1989.tb03478.x","type":"journal-article","created":{"date-parts":[[2012,7,27]],"date-time":"2012-07-27T00:02:04Z","timestamp":1343347324000},"source":"Crossref","is-referenced-by-count":0,"title":["Effects of chronic heart failure on the responsiveness to angiotensin I and to angiotensin converting enzyme inhibition with cilazapril in rats."],"prefix":"10.1111","volume":"27","author":[{"given":"JP","family":"Clozel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2012,7,26]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(84)80169-6"},{"key":"e_1_2_1_3_1","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1093\/oxfordjournals.eurheartj.a061975","article-title":"The renal response to neuroendocrine inhibition in chronic heart failure: double blind comparison of captopril and prazosin","volume":"7","author":"Bayliss J.","year":"1986","journal-title":"Eur. Heart J."},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198709000-00015"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/21.9.688"},{"key":"e_1_2_1_6_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.64.3.483"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.76.6.1344"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.63.3.645"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.1982.tb02075.x"},{"key":"e_1_2_1_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90895-7"},{"key":"e_1_2_1_11_1","first-page":"H341","article-title":"Effects of L\u2010thyroxine in rats with chronic heart failure after myocardial infarction","volume":"253","author":"Gay R.","year":"1987","journal-title":"Am. J. Physiol."},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1152\/ajpheart.1981.241.2.H273"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198605000-00030"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198601000-00016"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.72.2.364"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1097\/00000441-198609000-00001"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(84)90881-7"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005344-198505000-00025"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.74.4.766"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.RES.57.1.84"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.72.2.406"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(82)90052-7"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.5.3.312"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/000331976001100505"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198706043162301"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI108431"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.1989.tb03478.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.1989.tb03478.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,22]],"date-time":"2023-10-22T08:18:14Z","timestamp":1697962694000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.1989.tb03478.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1989,4]]},"references-count":25,"journal-issue":{"issue":"S2","published-print":{"date-parts":[[1989,4]]}},"alternative-id":["10.1111\/j.1365-2125.1989.tb03478.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.1989.tb03478.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[1989,4]]}}}